Altimmune Inc

Research Altimmune Inc (ALT) on Bullrun: market cap USD 571.75M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 571.75M
• Financial periodFY2025
• RevenueUSD 41.00K
• Revenue growth105.0%
• Net income-USD 88.09M
• Free cash flow-USD 67.55M

Valuation Snapshot

latest market cap is USD 571.75M.

About Altimmune Inc

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Frequently asked questions

What is Altimmune Inc's market cap?

Altimmune Inc's market capitalization is USD 571.75M.

What does Altimmune Inc do?

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.